Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies
Status:
Completed
Trial end date:
2014-05-31
Target enrollment:
Participant gender:
Summary
This is a two-arm, open-label study to determine the maximum tolerated dose (MTD) and assess
the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BMN 673 in
patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic
Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL). Arm 1 will enroll patients with
either AML or MDS; Arm 2 will enroll patients with either CLL or MCL.